MedPath

Inventiva Restructures: Halves Workforce to Focus on Late-Stage MASH Drug Lanifibranor

• French biotech Inventiva announces major restructuring, planning to lay off 50% of employees and discontinue all preclinical research except for its lead MASH candidate lanifibranor.

• Company's Phase III trial for lanifibranor in MASH has achieved over 95% patient randomization, with top-line results expected in second half of 2026.

• Strategic financial moves, including structured financing and milestone payments, combined with cost-cutting measures, expected to extend operations through Q3 2026.

In a significant strategic shift, French biotech Inventiva announced plans to reduce its workforce by half and narrow its focus exclusively to developing lanifibranor for metabolic dysfunction-associated steatohepatitis (MASH). The restructuring, scheduled for implementation in the second quarter, marks a crucial pivot for the company's future direction.

Strategic Pipeline Consolidation

The company will discontinue all preclinical research activities except those supporting the lanifibranor program. This decision includes terminating its oncology program, which had been investigating the disruption of YAP-TEAD interaction in the Hippo signaling pathway.

MASH Program Progress and Challenges

Inventiva's Phase III clinical trial for lanifibranor has made substantial progress, with patient screening completed in early January and over 95% of participants randomized. The company expects to complete enrollment in the first half of 2024, with top-line results anticipated in the second half of 2026.
However, the development program has faced challenges. In February 2024, the company voluntarily paused patient recruitment following a case of severe liver enzyme elevations. This pause came shortly before the FDA's March 2024 approval of Madrigal Pharmaceuticals' Rezdiffra (resmetirom), which became the first approved therapy for MASH.

Financial Position and Future Outlook

The company's financial performance shows a decline in revenue from 17.5 million euros in 2023 to 9.2 million euros in 2024. As of December 31, Inventiva maintained cash and cash equivalents of 96.6 million euros.
Looking ahead, Inventiva expects to strengthen its financial position in the second quarter through multiple sources:
  • Anticipated gross proceeds of approximately 116 million euros from a second tranche of structured financing
  • A 10 million dollar milestone payment from Chia Tai Tianqing Pharmaceutical Group, tied to their licensing agreement for lanifibranor development in China
These financial arrangements, combined with the workforce reduction and pipeline restructuring, are projected to sustain the company's operations through the end of the third quarter of 2026, aligning with the timeline for lanifibranor's Phase III results.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Inventiva Restructures to Focus on MASH Drug Development, Reports €96.6M Year-End Cash Position

Inventiva announces strategic pipeline prioritization, halting all preclinical research to focus exclusively on lanifibranor development for MASH treatment, with planned 50% workforce reduction.
Company reports €96.6 million cash position at 2024 year-end, securing operations until Q3 2025, with potential additional funding of €116 million expected in Q2 2025.

Ironwood Pharmaceuticals Cuts 50% of Workforce Amid Lower Revenue Projections, Focuses on Apraglutide Development

Ironwood Pharmaceuticals announces a major restructuring, including a 50% workforce reduction and discontinuation of the STARGAZE trial, as 2025 revenue guidance falls below analyst expectations. The company maintains focus on advancing apraglutide for short bowel syndrome, which showed promising Phase III results with a 25% reduction in parenteral support needs.

Zentalis Pharmaceuticals Restructures to Advance Azenosertib in Gynecological Cancers

Zentalis Pharmaceuticals is restructuring to prioritize the late-stage development of azenosertib, a WEE1 inhibitor, for gynecological malignancies.
The restructuring includes a workforce reduction of approximately 40% to extend the company's cash runway into late 2027.

Lexicon Pharmaceuticals Restructures, Cuts 60% of Staff After FDA Flags Zynquista Deficiencies

Lexicon Pharmaceuticals will lay off 60% of its workforce and disband its sales team to save $100 million, pivoting to focus on its research pipeline.
The restructuring follows an FDA letter citing deficiencies in Lexicon's approval application for its diabetes drug, Zynquista (sotagliflozin).

Aurinia Pharmaceuticals Restructures, Cutting 45% of Workforce to Focus on Lupkynis and AUR200

Aurinia Pharmaceuticals is reducing its workforce by 45% to save over $40 million annually, streamlining operations to focus on key assets.
The restructuring prioritizes the growth of Lupkynis (voclosporin) for lupus nephritis and the clinical validation of AUR200 for autoimmune diseases.

Relay Therapeutics Announces Workforce Reduction to Streamline Research

Relay Therapeutics is laying off approximately 10% of its workforce, affecting about 30 employees, as part of a streamlining effort to enhance research efficiency.
The restructuring aims to save the company around $50 million annually, following a reported net loss of $92.2 million in the second quarter of 2024.

IN8bio Restructures to Focus on INB-100 AML Program Following $12.4 Million Private Placement

IN8bio is prioritizing its INB-100 program for acute myeloid leukemia (AML) due to promising results and a challenging financing environment.
The company is reducing its workforce by approximately 49% and pausing its glioblastoma multiforme (GBM) program to cut costs.

Repare Therapeutics Prioritizes Clinical Oncology Pipeline, Streamlining Operations

Repare Therapeutics is focusing on its clinical-stage oncology programs, including lunresertib, camonsertib, RP-1664, and RP-3467, to maximize value for patients and shareholders.
The company plans to reduce its workforce by approximately 25%, mainly from the preclinical group, to extend its cash runway into the second half of 2026.

Intellia Announces Workforce Reduction and Research Pause

Intellia Therapeutics, a leader in CRISPR gene editing technology, has announced a 15% workforce reduction and a pause on some early-stage research. This decision comes shortly after receiving U.S. regulatory approval for a late-stage clinical trial of its leading drug candidate, NTLA-2001, aimed at treating ATTR amyloidosis. The company plans to focus on NTLA-2001 and other priority programs, despite the challenges faced in the biotech sector.

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy